Gene Therapies for CMT

Gene therapies are a means to treat disease by modifying the genetic machinery of cells in the body. The goal is to target the underlying genetic cause of disease, which can be accomplished via repair of a genetic defect or replacement of missing or defective genes with healthy, fully functional ones. This in turn enables the normal expression and function of critical proteins.

There are a number of different types of gene therapy. Some of those under development right now include:

  • Gene Editing is a precise method of targeting a gene mutation by inserting, removing, or replacing specific pieces of DNA within the faulty gene itself.
  • Gene Knockdown, or the reduction of gene expression resulting in reduced protein production, can be achieved during the protein manufacturing process during either transcription or translation via a strategy known as RNA interference (RNAi).
  • Gene Replacement is a technique in which the addition of a new, working copy of a gene into target cells serves as a healthy replacement for a missing or mutated gene. The new gene is manufactured in the laboratory and transported to the nucleus of targeted cells, where its code can be read and its instructions for protein production implemented. This type of therapy may be used  in loss-of-function disorders caused by a missing or defective gene and the subsequent deficiency or insufficiency of that gene’s normal product. The introduction of the healthy gene is intended to result in production of a sufficient amount of properly functioning protein.

Transportation of genetic material to target cells is an incredibly important part of the gene therapy approach. Small viruses often serve as vectors, or transport vehicles, capable of delivering genetic material “cargo” to its destination either into a cell’s existing DNA or into its nucleus. Many scientists currently are working with adeno-associated viral (AAV) vectors, which are able to penetrate the cell’s nucleus and aren’t known to cause diseases in people. However, their small size limits the amount of genetic material they can carry.

Risks are inherent with any treatment, and gene therapy is no exception. However, it likely won’t be possible to “turn off” gene therapy, which is why it’s critical to study methods of administration, the genetic material to be delivered or altered, a patient’s disease stage and other aspects of his or her genetic makeup.

CMT Research Foundation is leading the charge to ensure safe and effective therapies for all forms of CMT make it to the market to help those living with CMT today. We are working every day to support the families, the foundations, the academics, the scientists, the biotechs and the pharma companies who share our goal and who are working to make it happen.

Related News & Research

Hope Alone Won’t Save My Hands, But a Treatment Will

I heard a loud pop. Then came the sudden swelling. All I’d been doing was walking down the sidewalk when my left leg snapped. At first, I thought it was just sprained. I kept limping on it for two weeks, until a doctor confirmed it was broken. Doctors gave me three options: Live with the pain and wear a removable cast for the rest of my life, undergo another surgery that probably won’t work, or amputate a portion of my leg. I chose amputation. Read more about Joe’s journey and what he’s doing to give people with CMT more than hope.

Thank You for Giving Me More Than Hope

This year has brought great momentum in the fight against CMT. At the CMT Research Foundation, we are hearing from scientists that it feels like something special is in the air. Conferences and journals are full of new discoveries, fundamental problems in CMT are being solved, new genes are being discovered, and new drugs are being developed. Read more about the progress.

How We Get from Today to Approved CMT Treatments: An Interview with FDA Director Dr. Peter Marks

The CMT Research Foundation is asking and answering the most pressing questions patients have about the need for treatments and cures. In episode 3, CMT Research Foundation CEO Susan Ruediger interviews the FDA’s Dr. Peter Marks to discuss gene therapies as a potential treatment option for CMT, what the approval process looks like and how patients can expedite it.

Curcumin and CMT: What You Need to Know

“Should I be taking curcumin supplements or eating more turmeric?” Many people with Charcot-Marie-Tooth disease (CMT) have been asking this question after researchers recently published a paper about curcumin and CMT in the journal Free Radical Biology and Medicine. The CMT Research Foundation’s chief scientific officer explores the findings and what it means for people with CMT.

CMT Research Foundation Launches New Research Project to Design Precision Medicine Approach for Charcot-Marie-Tooth Disease

In this new CMT Research Foundation-funded project, Drs. Lorson and Garcia at the University of Missouri will develop and test a new gene therapy approach that will both silence the abnormal gene and simultaneously replace it with genetic material that will produce normal protein. The research team will test this approach in an animal model of CMT2E that is already well understood, making it suitable for this proof-of-concept project. If the approach is successful, it could potentially be used for other forms of CMT as well. In fact, it is possible this approach could be used for many CMT-causing mutations that require both silencing of a mutated gene and replacement with normal protein — whether the mutation is currently known or has yet to be discovered. The ability to silence and replace genes, regardless of the specific mutation, is what makes this a precision medicine approach.